Association between sigma-1 receptor gene polymorphism and prefrontal hemodynamic response induced by cognitive activation in schizophrenia.
The molecular biological role of the sigma-1 receptor (Sig-1R) has attracted much attention. Evidence suggests that the Sig-1R engaged in modulating NMDA and dopamine receptors is involved in the pathophysiology of schizophrenia and the mechanism of psychotropic drug efficacy. However, whether the Sig-1R genotype affects brain function in schizophrenia in vivo remains unknown. We investigated the association between Sig-1R functional polymorphism (Gln2Pro) and brain function in schizophrenia. The subjects were 40 patients with schizophrenia and 60 healthy controls, all right-handed, who gave written informed consent to participate. Signals, detected from prefrontal regions by 52-channel near-infrared spectroscopy (NIRS) during cognitive activation, were compared between two Sig1-R genotype subgroups (Gln/Gln individuals and Pro carriers) matched for age, gender, premorbid IQ and task performance. The prefrontal hemodynamic response of healthy controls during the verbal fluency task was higher than that of patients with schizophrenia. For the patients with schizophrenia, even after controlling the effect of medication, the [oxy-Hb] increase in the prefrontal cortex of the Gln/Gln genotype group was significantly greater than that of the Pro carriers (false discovery rate corrected p<0.05). Clinical symptoms were not significantly different between the two Sig-1R genotype subgroups. These differences were not significant in the healthy controls. This is the first functional imaging genetics study that implicated the association between Sig-1R genotype and prefrontal cortical function in schizophrenia in vivo. Our findings also suggest that the prefrontal hemodynamic response assessed by noninvasive and less demanding NIRS is a useful intermediate phenotype for translational research in schizophrenia.
Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Japan. takizawar-tky@umin.ac.jp
Ryu
R
Takizawa
Kenji
K
Hashimoto
Mamoru
M
Tochigi
Yuki
Y
Kawakubo
Kohei
K
Marumo
Tsukasa
T
Sasaki
Masato
M
Fukuda
Kiyoto
K
Kasai
D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents; D001931:Brain Mapping; D016009:Chi-Square Distribution; D002746:Chlorpromazine / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects / Q000502:physiology*; D005260:Female; D005838:Genotype; D005973:Glutamine / Q000235:genetics; D006439:Hemodynamics / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010108:Oxyhemoglobins; D011110:Polymorphism, Genetic / Q000235:genetics*; D017397:Prefrontal Cortex / Q000098:blood supply*; D011392:Proline / Q000235:genetics; D017480:Receptors, sigma / Q000235:genetics*; D012559:Schizophrenia / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D019265:Spectroscopy, Near-Infrared / Q000379:methods; D014705:Verbal Behavior / Q000502:physiology; D000097605:Sigma-1 Receptor
D014150:Antipsychotic Agents; D002746:Chlorpromazine; D005973:Glutamine; D010108:Oxyhemoglobins; D011392:Proline; D017480:Receptors, sigma; D000097605:Sigma-1 Receptor